Related Experiment Videos
Laparoscopic splenectomy in patients with hematologic malignancies.
R S Berman1, A M Yahanda, P F Mansfield
1Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
American Journal of Surgery
|February 12, 2000
Summary
Laparoscopic splenectomy (LS) is feasible for hematologic malignancies, showing similar morbidity and mortality to open surgery. Shorter hospital stays may allow for earlier cancer treatment.
Area of Science:
- Surgical Oncology
- Minimally Invasive Surgery
- Hematology
Background:
- The role of laparoscopic splenectomy (LS) in hematologic malignancies remains unclear.
- LS is widely accepted for benign hematologic conditions.
Purpose of the Study:
- To evaluate the efficacy and feasibility of LS in patients with hematologic malignancies.
Main Methods:
- Retrospective review of patients undergoing LS at two university hospitals.
- Comparison with 77 open splenectomies (OM) for malignancy.
Main Results:
- 22 patients with hematologic malignancies (LM) underwent LS.
- LM had longer operative times, greater blood loss, and a 41% conversion rate compared to benign cases.
- Morbidity, mortality, and transfusion rates were similar between LM and benign cases.
- Median hospital stay for LM was shorter (4 days) than for OM (6 days).
Conclusions:
- LS is a feasible surgical option for hematologic malignancies.
- While associated with increased operative time and blood loss, LS offers comparable safety to open surgery.
- Shorter hospitalizations following LS may facilitate earlier initiation of antineoplastic therapy.